Lifastuzumab vedotin
Lifastuzumab vedotin is an antibody-drug conjugate designed to treat cancer. It is composed of the monoclonal antibody lifastuzumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). The antibody portion of the drug binds to HER3, a protein that is overexpressed in certain types of cancer, and delivers the cytotoxic agent directly to the cancer cells.
Mechanism of action
Lifastuzumab vedotin works by targeting the HER3 protein on the surface of cancer cells. The lifastuzumab portion of the drug binds to HER3, and the drug is then internalized by the cell. Once inside the cell, the MMAE is released and interferes with cell division, leading to cell death.
Clinical trials
Lifastuzumab vedotin has been tested in clinical trials for the treatment of various types of cancer, including breast cancer, lung cancer, and gastric cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.
Side effects
The most common side effects of lifastuzumab vedotin include fatigue, nausea, and decreased appetite. More serious side effects can include neutropenia, peripheral neuropathy, and pulmonary toxicity.
See also
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
